Ianalumab: Breakthrough Therapy in Sjogren's Save

Dr. Yuz Yusof reports on abstract LB24 (Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)), presented at the 2025 ACR Convergence meeting in Chicago.